Αναζήτηση Δραστικών

DAPTOMYCIN

Εμπορικές Ονομασίες

  • DRUGBANK - Daptomycin
  • indication:

    For the treatment of complicated skin and skin structure infections caused by susceptible strains of Gram-positive microorganisms.

  • pharmacology:

  • mechanism:

    Daptomycin appears to bind or insert into the outer membrane of gram positive bacteria. The binding and integration of daptomycin into the cell membrane is calcium dependent. Calcium ions cause a conformational change in daptomycin, augmenting its amphipathicity (hydrophilic head group and hydrophobic tail group), leading to incorporation into the cell membrane. This binding causes rapid depolarisation, resulting in a loss of membrane potential leading to inhibition of protein, DNA and RNA synthesis, which results in bacterial cell death. The bactericidal activity of daptomycin is concentration-dependent. There is in vitro evidence of synergy with β-lactam antibiotics.

  • toxicity:

  • absorprion:

  • halflife:

    7 days

  • roouteelimination:

    Daptomycin is excreted primarily by the kidney. In a mass balance study of 5 healthy subjects using radiolabeled daptomycin, approximately 78% of the administered dose was recovered from urine based on total radioactivity (approximately 52% of the dose based on microbiologically active concentrations) and 5.7% of the dose was recovered from feces (collected for up to 9 days) based on total radioactivity. Because renal excretion is the primary route of elimination, dosage adjustment is necessary in patients with severe renal insufficiency (CLCR <30 mL/min)

  • volumedistribution:

    * 0.1 L/Kg [healthy adult subjects]

  • clearance: